symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ADIL,2.92,1.0318,74521,3556502,0,2.44-15.0,-0.07,"Adial Pharmaceuticals, Inc.",USD,0001513525,US00688A1060,00688A106,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.adialpharma.com,"Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.",Mr. Cary John Claiborne MBA,Healthcare,US,16,434 422 9800,1180 Seminole Trail,Charlottesville,VA,22901,0.490387,2.33039,https://financialmodelingprep.com/image-stock/ADIL.png,2018-07-27,False,False,True,False,False
